miR-182 has been shown to specifically target FOXO transcription factors irrespective of cell type, since miR-182 seems to target FOXO3 in melanoma cells, FOXO1 in breast cancer cells and FOXO1 in activated helper T (Th) lymphocytes90. Here, FOXO3 is linked to breast carcinoma.